Gilead's Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients

  • Gilead Sciences Inc GILD announced results reinforcing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a highly efficacious treatment option for HIV, including individuals with HIV/hepatitis B (HBV) coinfection. 
  • Interim data from the ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection who were initiating therapy show potential HBV and HIV suppression comparable to an alternative HIV regimen. 
  • Related: Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues.
  • Additionally, 5-year data from two Phase 3 trials further demonstrated Biktarvy's sustained efficacy, safety profile, and high barrier to resistance in adults with HIV initiating therapy.
  • Participants who initiated treatment with Biktarvy versus DTG+F/TDF demonstrated superior HBV DNA suppression (63% vs. 43%) and hepatitis B e-antigen (HBeAg) seroconversion (23% vs. 11%).
  • No cases of treatment failure due to emergent resistance were detected in an analysis of five years of data.
  • Also Read: Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions.
  • Price Action: GILD shares are down 0.36% at $60.67 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!